6,465 Shares in Merck & Company, Inc. (NYSE:MRK) Acquired by Bank Hapoalim BM
Bank Hapoalim BM acquired a new position in Merck & Company, Inc. (NYSE:MRK) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 6,465 shares of the company’s stock, valued at approximately $411,000.
A number of other large investors have also recently modified their holdings of the company. Macquarie Group Ltd. increased its stake in shares of Merck & by 4.1% in the fourth quarter. Macquarie Group Ltd. now owns 12,753,649 shares of the company’s stock worth $750,807,000 after buying an additional 506,952 shares during the last quarter. RB Capital Management LLC purchased a new stake in shares of Merck & during the fourth quarter worth about $263,000. AE Wealth Management LLC purchased a new stake in shares of Merck & during the fourth quarter worth about $1,741,000. First PREMIER Bank increased its stake in shares of Merck & by 2.7% in the first quarter. First PREMIER Bank now owns 21,475 shares of the company’s stock worth $1,364,000 after buying an additional 570 shares during the last quarter. Finally, Blue Edge Capital LLC purchased a new stake in shares of Merck & during the fourth quarter worth about $744,000. 73.73% of the stock is owned by institutional investors and hedge funds.
Shares of Merck & Company, Inc. (NYSE:MRK) opened at 63.10 on Monday. The stock has a market capitalization of $172.59 billion, a PE ratio of 34.16 and a beta of 0.80. The firm has a 50-day moving average of $63.65 and a 200 day moving average of $63.78. Merck & Company, Inc. has a 1-year low of $57.18 and a 1-year high of $66.80.
Merck & (NYSE:MRK) last released its earnings results on Friday, July 28th. The company reported $1.01 EPS for the quarter, topping the consensus estimate of $0.87 by $0.14. Merck & had a net margin of 17.14% and a return on equity of 25.75%. The firm had revenue of $9.93 billion for the quarter, compared to the consensus estimate of $9.75 billion. During the same quarter in the previous year, the firm earned $0.93 earnings per share. The company’s quarterly revenue was up .9% compared to the same quarter last year. Analysts predict that Merck & Company, Inc. will post $3.87 EPS for the current year.
The business also recently announced a quarterly dividend, which will be paid on Friday, October 6th. Stockholders of record on Friday, September 15th will be issued a $0.47 dividend. This represents a $1.88 annualized dividend and a dividend yield of 2.98%. The ex-dividend date of this dividend is Thursday, September 14th. Merck &’s dividend payout ratio (DPR) is presently 76.11%.
TRADEMARK VIOLATION NOTICE: “6,465 Shares in Merck & Company, Inc. (NYSE:MRK) Acquired by Bank Hapoalim BM” was originally published by Daily Political and is the property of of Daily Political. If you are viewing this story on another publication, it was copied illegally and republished in violation of US & international trademark and copyright legislation. The original version of this story can be viewed at https://www.dailypolitical.com/2017/08/07/6465-shares-in-merck-company-inc-nysemrk-acquired-by-bank-hapoalim-bm.html.
MRK has been the subject of a number of recent analyst reports. J P Morgan Chase & Co upped their price objective on shares of Merck & from $74.00 to $76.00 and gave the stock an “overweight” rating in a research report on Thursday, May 11th. Zacks Investment Research downgraded shares of Merck & from a “buy” rating to a “hold” rating in a research report on Wednesday, August 2nd. Credit Suisse Group reissued a “buy” rating on shares of Merck & in a research report on Tuesday, June 13th. Vetr raised shares of Merck & from a “sell” rating to a “strong-buy” rating and set a $71.50 target price for the company in a research report on Monday, May 15th. Finally, Cowen and Company reissued a “market perform” rating and set a $70.00 target price (up from $68.00) on shares of Merck & in a research report on Thursday, May 11th. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and twelve have given a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $69.80.
In other news, Director C Robert Kidder sold 5,000 shares of the business’s stock in a transaction on Friday, May 12th. The shares were sold at an average price of $63.54, for a total value of $317,700.00. Following the transaction, the director now owns 14,317 shares of the company’s stock, valued at $909,702.18. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 0.05% of the stock is currently owned by insiders.
Merck & Company Profile
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Company, Inc. (NYSE:MRK).
Receive News & Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related companies with MarketBeat.com's FREE daily email newsletter.